Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
about
sameAs
The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic CancerThe Role of PPARs in CancerDLC-1: a Rho GTPase-activating protein and tumour suppressorThe role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionThe peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseasesMolecular Targeted Therapies of Aggressive Thyroid CancerPeroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a reviewChemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancerPPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic DrugsCommonalities in the Association between PPARG and Vitamin D Related with Obesity and CarcinogenesisFunctions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic DisordersThe non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesProline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanismsCombined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cellsPeroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transitionCOX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situRegulatory subunits of PKA define an axis of cellular proliferation/differentiation in ovarian cancer cellsThe investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imagingModulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma.Therapeutic Implications of PPARgamma in Human Osteosarcoma.In vivo effects of rosiglitazone in a human neuroblastoma xenograft.Energy restriction as an antitumor target of thiazolidinediones.Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis.Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancerPPARγ in head and neck cancer preventionGene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.Novel approaches in anaplastic thyroid cancer therapySkin phototype: a new perspective.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer.Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancerCellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.Role of traditional and new biomarkers in breast carcinogenesis.Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.Peroxisome proliferator activated receptor γ protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation.PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia
P2860
Q21342813-D12C0403-AF04-4AB7-9E0F-C6F1EE34413AQ21342955-10EBEC04-5C82-44E0-9271-959CF9C32C2CQ23917637-D1C48131-532C-4833-9F1D-A1AB9344737AQ24601222-D3C9B820-51FD-4D40-910F-F8BF3A33E06CQ24612698-0F8859BF-8184-43FF-A161-58661034E2A0Q26774734-0DC3EDCF-5082-43F7-8B36-D2B676FFA311Q26866784-55238EB4-0475-44EB-9C09-912030D4D6A5Q27026428-A62E59B4-5760-4DD2-8F9C-9E4D0B12B4F3Q28066756-C23FDE23-DC8D-42F6-86EE-9C121E7E0E7FQ28070220-AAED2C78-EC59-45DD-BB94-F0CB2687BF08Q28082264-9862D673-F2E6-4328-A2BA-5B4D0011DE91Q28238709-9932A90A-935E-4FCC-B339-D5ED165E19A2Q28283135-8A7AC632-167B-43AC-A8E6-4AB3083FE4EBQ28543879-62391FD4-3A85-40B1-8CB9-F04045E9D2BCQ30498249-C73FCD81-CFD5-4CD3-871A-3146389AF829Q33317621-FB67E7C2-716F-443D-BE9F-883709FCF6D9Q33372446-2E14B09B-4789-467D-94C6-E5D26668D0A5Q33540291-7408BF71-4157-45A1-9546-F61B7CB2B0E7Q33575523-57984D53-D495-4474-B600-31406D5BD117Q33674615-3B463A8C-51D8-4DCA-BB6A-44FF01B3ECABQ33723620-7DF2A1B0-397A-4923-A2A1-7584FF7B6BB3Q33744668-D1B3DBEB-4374-4B3D-9F84-A999965578EFQ33830757-80678E49-48B6-4ECC-9AF6-5BC8C58A494EQ33837550-80100543-497C-49B5-AE3F-DE278AD8AD2DQ33896090-56CA2C0B-87CE-40FE-A81A-DA049436AE39Q34235817-88901F13-628C-4FBF-9F96-FFD38F58322EQ34420463-28FA5402-6DB6-4330-A365-BA9C563A086FQ34458018-93DD02CE-CA89-4D55-B2CB-6CD8CA13B380Q34467780-6FED4FD6-5B1A-4029-ACFC-15787EAE47EBQ34646050-AA80D2EB-3D84-4281-A9BA-F747A93966ECQ34685755-85459ABB-3A3B-49D8-A653-2184BA4B83A1Q35051779-A68F99AF-1179-4AD5-8F1E-C76BE756EDD7Q35092571-A05944D4-8664-4D90-8C8E-E5A50235A0E3Q35168034-4BBE9119-9EF6-4D92-9913-606789B7FCABQ35249254-BDA43AFA-E7B0-4507-BB70-0B5073B378CEQ35572905-7D829581-0F86-4F82-B9A8-484445D32E65Q35750111-10016750-A262-4242-B46A-FE004CEAFB07Q35763145-F4E4CA3B-D8A0-4BF7-87D9-1F85A8702CD0Q35927161-739A590A-48D1-4750-B336-FBA87FF8B2D9Q35943219-DE2B1DCD-F734-4CF9-89CB-D4E113A686D8
P2860
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@ast
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@en
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@nl
type
label
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@ast
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@en
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@nl
altLabel
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
@en
prefLabel
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@ast
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@en
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@nl
P3181
P1433
P1476
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
@en
P2093
Gary E Landreth
Michael T Heneka
P304
P3181
P356
10.1016/S1470-2045(04)01509-8
P407
P50
P577
2004-07-01T00:00:00Z